When it was all about printing up 300 copies of an obscure journal and making sure that they got to the only 300 people in the world interested in the subject there was a possible argument in favour ofthemodel.
Dr Magiorkinis, who did the work in collaboration with the University of Athens and Imperial College London, said themodel had helped build a "solid argument" to improve early diagnosis and antiviral treatment in drug users.
No matter how good a stock sounds, if an m100 member is not willing to put a portion of their model portfolio into the stock in question, their argument loses credibility with me.